Can chinese medicine and exercise heal Immunotherapy-Damaged hearts?
NCT ID NCT07280429
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a rehabilitation program for cancer patients who developed heart inflammation (myocarditis) from immunotherapy drugs. The program combines a Chinese herbal formula (Shengxian Quyu therapy) with traditional exercises like Baduanjin. Researchers will measure heart health, quality of life, and major heart events in 60 participants over 2 weeks.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- rehabilitation protocol (Shengxian Quyu therapy and traditional Chinese exercise like Baduanjin)
- What this could lead to
- If it works, this could point toward a safe way to improve heart function and quality of life for cancer patients recovering from immunotherapy-related heart inflammation.
- What could go wrong
- This is a small, early-stage trial with only 60 participants, so results may not apply to everyone. The rehab includes traditional Chinese medicine, which may not be widely accepted or effective in all settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jan 2026
An estimate. Start dates often move.
- Expected to finish
-
Jul 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * ①Aged 18 to 80 years, inclusive.②Malignancy confirmed by cytology or histopathology.③Diagnosis of ICIAM following ICI therapy.④Assessed by the Multidisciplinary Team for Immune-Related Adverse Events as clinically recovered and entering the rehabilitation.⑤Meet TCM syndrome differentiation criteria for "Yangqi Deficiency with Internal Retention of Phlegm and Stasis."⑥ KPS score \> 60, with a life expectancy \> 6 months. Exclusion Criteria: * ①Diagnosis of fulminant myocarditis or cardiac function of NYHA IV.②Clear evidence suggesting cardiac injury not attributable to ICIs.③Concurrent acute cardiovascular events or malignant arrhythmias.④Coexisting severe immune-related adverse events affecting other organ systems.⑤Associated severe systemic diseases, such as severe hepatic or renal insufficiency, or severe infection.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Immune checkpoint inhibitors related myocarditis are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.